微创肾癌手术后患者报告的生活质量与康复过程
结果显示术后2周两组整体CARE及疼痛、胃肠、活动领域评分显著下降,4周时仅50%患者整体CARE恢复至基线,12周时根治组82%、部分切除组76%恢复至基线。
要点
- 微创肾癌术后康复常超过4周,部分切除与根治性切除均如此。
- 术后4周仅半数患者整体CARE评分恢复至基线水平。
- 术前咨询应告知患者康复可能延长,以提高满意度。
核心结论
- 微创肾癌手术(部分或根治性切除)后康复常持续超过4周,此信息可用于更准确的术前咨询。
研究设计与样本
- 使用CARE问卷和SF-12在基线及术后2、4、8、12周评估,采用混合重复测量模型分析。
主要发现
- 术后2周两组整体CARE及疼痛、胃肠、活动领域评分显著下降,4周时仍略低于基线。
- 术后4周仅50%患者整体CARE评分恢复至基线。
- 术后12周根治性肾切除组82%、部分肾切除组76%患者整体CARE恢复至基线。
临床怎么用
- 利用上述康复时间数据为患者提供术前咨询,告知康复可能超过4周。
- 关注术后4周时仍有一半患者未恢复至基线生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To better characterize recovery after minimally invasive kidney surgery, we present a study describing patient-reported health-related quality of life (HRQOL) following minimally invasive radical nephrectomy (RN) and partial nephrectomy (PN). METHODS: Patients who underwent minimally invasive PN or RN for renal cancer were invited to enroll in a prospective, patient-reported HRQOL study using the Convalescence and Recovery Evaluation (CARE) instrument and Short Form-12. Patients completed questionnaires at baseline, 2, 4, 8, and 12 weeks after surgery. Mixed repeated measures model were used to assess time effect on HRQOL scores and predictors of scores within each surgery groups. RESULTS: One hundred seventy-seven patients were included in the study: 50 had RN and 127 had PN. At 2 weeks, both groups had significant decreases in Overall CARE, as well as the Pain, Gastrointestinal, and Activity domain scores which remained slightly below baseline at 4 weeks. At 4 weeks only 50% of patients in both the RN and PN cohorts returned to baseline overall CARE score. By 12 weeks 82% returned to baseline overall CARE score in the RN group while 76% of patients did so in the PN group. CONCLUSION: Convalescence after minimally invasive renal surgery can often extend beyond 4 weeks post-treatment in PN and RN subjects. This information may be used to provide more accurate preoperative counseling in an attempt to improve overall patient satisfaction.
引用
- Althaus AB, Chang P, Mao J, et al. Patient-Reported Quality of Life and Convalescence After Minimally Invasive Kidney Cancer Surgery. Urology. 2020. PMID: 32603743. doi:10.1016/j.urology.2020.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。